Physician profile
Maria Dats
NPI 1528574035
$1,649.39
in general payments reported to CMS, 2019-2025
24 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.89 · 2022: $282 · 2023: $783 · 2024: $152 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $234.32 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $189.36 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.79 | 2021-2023 | Jardiance |
| Exact Sciences Corporation | $148.80 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $131.26 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $95.79 | 2022-2024 | |
| Medtronic, INC. | $88.73 | 2025 | Minimed 780g |
| Abbvie INC. | $80.77 | 2023-2024 | |
| Astellas Pharma US INC | $72.48 | 2022-2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $67.66 | 2022-2023 | Shingrix, Arexvy |
| Sequel Med Tech, LLC | $62.78 | 2025 | Twiist |
| Amgen INC. | $55.98 | 2022-2024 | Otezla, Repatha |
| Mannkind Corporation | $35.34 | 2025 | |
| Corcept Therapeutics | $25.60 | 2023 | Korlym |
| Otsuka America Pharmaceutical, INC. | $25.18 | 2023 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $24.99 | 2023 | Inspire |
| Kyowa Kirin, INC. | $23.75 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.64 | 2023 | Trintellix |
| Ascendis Pharma Endocrinology INC | $19.82 | 2025 | Yorvipath |
| Idorsia Pharmaceuticals US INC | $17.96 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $14.89 | 2021 | |
| Merck Sharp & Dohme LLC | $14.66 | 2021 | |
| Amarin Pharma, INC. | $14.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Dats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.